โ† All MTM Flashcard Decks

Regulatory Compliance & Ethical Standards Flashcards

7 cards from real MTM practice questions. Tap to flip, then mark Knew It or Still Learning โ€” missed cards come back until you master them.

Read the first 7 Regulatory Compliance & Ethical Standards flashcards as text
  1. A pharmacist's MTM employer instructs staff to bill for Targeted Medication Reviews (TMRs) that were never performed. Which whistleblower protection law is MOST relevant to a pharmacist who reports this internally and then externally?

    Answer: False Claims Act qui tam provisions

    The False Claims Act's qui tam provisions allow and protect whistleblowers who report fraud against federal health programs, entitling them to a portion of recovered funds.

  2. Which principle of beneficence-based ethics BEST describes the obligation to actively prevent harm to a patient during MTM, rather than just avoiding it?

    Answer: Positive beneficence

    Positive beneficence requires active efforts to benefit patients and prevent harm, going beyond the more passive non-maleficence standard of merely avoiding harm.

  3. A patient enrolled in MTM is also enrolled in a clinical trial. How should the MTM pharmacist handle medications the patient receives as a trial participant?

    Answer: Document trial medications, assess interactions with regular medications, and coordinate with the trial team

    MTM pharmacists should document and assess all medications including investigational drugs for interactions, coordinating with the clinical trial team to ensure patient safety.

  4. The CMS Star Ratings program evaluates Part D plan quality, including MTM metrics. Which pharmacist behavior MOST directly contributes to improving a plan's Star Rating related to MTM?

    Answer: Ensuring high-quality CMR completion rates with documented follow-up and patient engagement

    Star Ratings reward high CMR completion rates with genuine patient engagement and documented outcomes, not just procedural completion for metric timing.

  5. In an MTM setting, a pharmacist realizes a patient lacks decision-making capacity. Who is the appropriate surrogate decision-maker in the absence of a designated healthcare proxy?

    Answer: The next of kin in accordance with state law hierarchy (typically spouse, then adult children)

    When no healthcare proxy is designated, state laws typically establish a hierarchy of surrogate decision-makers, usually beginning with the spouse or closest adult relative.

  6. A state board of pharmacy investigation finds a pharmacist failed to document MTM interventions per state administrative code. This violation primarily falls under which category of law?

    Answer: State administrative/regulatory law

    State board of pharmacy rules and administrative codes are sources of state administrative/regulatory law governing pharmacy practice within that state.

  7. Which scenario BEST illustrates the ethical principle of justice in MTM program design?

    Answer: Ensuring MTM services are equitably accessible to all eligible patients regardless of socioeconomic status

    Justice in healthcare requires fair and equitable distribution of services; MTM programs must not discriminate based on socioeconomic or other non-clinical factors.